Elanco's Canine Parvovirus Treatment Gets USDA License

RTTNews | 832天前

(RTTNews) - Elanco Animal Health Inc. announced that the U.S. Department of Agriculture or USDA has issued a conditional license for its Canine Parvovirus Monoclonal Antibody.

The company expects to begin shipping Canine Parvovirus Monoclonal Antibody in the coming weeks, pending individual state approvals.

The targeted single-dose monoclonal antibody is the first and only approved targeted therapeutic solution proven to treat deadly dog disease. The conditional license approval was granted by the USDA to effectively and safely meet an emergency situation, limited market or special circumstance.

It is the first monoclonal antibody for Elanco, which recently received the U.S. Food and Drug Administration's conditional approval for its Varenzin-CA1 to treat anemia in cats with chronic kidney disease.

The USDA conditional license is based on clinical trials that demonstrate the Canine Parvovirus Monoclonal Antibody single, intravenous dose delivers targeted efficacy in treating canine parvovirus.

In the treatment efficacy study, the Canine Parvovirus Monoclonal Antibody was proven effective in decreasing mortality associated with parvovirus infection.

The company noted that the treatment can be administered to dogs eight weeks of age or older with canine parvovirus. According to the firm, the treatment may provide a less intensive and more effective solution than supportive care alone by targeting the virus with single dose efficacy and a strong safety profile in healthy dogs.

Elanco will also continue to provide canine parvovirus education and resources to veterinarians, shelter owners and pet parents.

Canine parvovirus is one of the most contagious and deadly viruses a dog can contract with a 91 percent mortality rate if not treated with supportive care. Annually, an estimated 330,000 cases of canine parvovirus are reported for treatment in the U.S. Prior to Elanco's Canine Parvovirus Monoclonal Antibody, the only treatment for the highly contagious canine parvovirus was supportive therapy, which can consist of 24/7 care and multi-day hospitalization.

Kristin Zersen, assistant professor of small animal emergency and critical care at Colorado State University Veterinary Teaching Hospital, said, "Parvovirus is an unpredictable disease that causes significant strain on pet owners and is labor intensive and stressful for shelters and veterinary clinic staff. It's lifechanging and industry-defining to be able to offer a proven solution to canine parvovirus that limits the need for hospitalization, reducing the impact this disease has on hundreds of thousands of dogs each year."

For More Such Health News, visit rttnews.com

標籤: ELAN

Elanco Animal Health Closes Sale Of Aqua Business To Merck Animal Health

Elanco Animal Health, Inc. (ELAN) announced Tuesday it has completed the divestiture of its aqua business to Merck Animal Health (MRK) for approximately $1.3 billion in cash, with approximately $1.05 billion to $1.1 billion in net proceeds available for debt paydown in the third quarter of 2024.

RTTNews | 399天前

Elanco Animal Health Boosts FY23 Adj. EPS, Revenue Outlook As Q3 Results Top Estimates

Elanco Animal Health Inc. (ELAN) reported Tuesday a net loss for the third quarter of $1.10 billion or $2.22 per share, sharply wider than $65.0 million or $0.13 per share in the prior-year quarter.

RTTNews | 644天前

FDA Approves First Drug For Anemia In Cats With CKD

The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD. It is the first drug for the control of nonregenerative anemia associated with CKD in cats. Varenzin-CA1 works by helping to increase production of erythropoietin in the kidney, which in turn stimulates the bone mar

RTTNews | 833天前

UK Labor Market Cools In Q2

The U.K. labor market softened in the second quarter as wage growth eased, the unemployment rate held steady at a four-year high and job vacancies continued to decline sharply, official data revealed on Tuesday. The ILO jobless rate held steady at 4.7 percent in the second quarter, figures from the Office for National Statistics revealed and was in line with expectations.

RTTNews | 55秒前

U.S. Consumer Prices Increase 0.2% In July, In Line With Estimates

Consumer prices in the U.S. increased in line with economist estimates in the month of July, according to a report released by the Labor Department on Tuesday. The Labor Department said its consumer price index rose by 0.2 percent in July after climbing by 0.3 percent in June. The modest increase matched expectations.

RTTNews | 12分鐘前

Cardinal Health Lifts FY26 Outlook, But Stock Down As Q4 Revenues Miss Street; To Buy Solaris Health

Shares of Cardinal Health, Inc. were losing around 6% in the pre-market activity after the company's fourth-quarter top line missed the market view, even as profit beat the Street. In addition, the health care service provider raised its fiscal 2026 outlook, also above market estimates. Separately, Cardinal Health announced that its multi-specialty management services organization or MSO platform

RTTNews | 36分鐘前

U.S. Consumer Prices Increase In Line With Estimates In July

Consumer prices in the U.S. increased in line with economist estimates in the month of July, according to a report released by the Labor Department on Tuesday.

RTTNews | 56分鐘前

German ZEW Economic Confidence Deteriorates On Trade Deal

Economic sentiment in Germany deteriorated sharply in August due to the disappointing trade agreement reached with the United States, and also due to the declining economic output in the second quarter, results of the monthly survey conducted by the think tank ZEW showed on Tuesday. The ZEW Indicator of Economic Sentiment plummeted to a three-month low of 34.7 in August.

RTTNews | 1小時31分鐘前

EURUSD	1.16265	GBPUSD	1.34694	AUDUSD	0.64958
USDJPY	148.405	USDCAD	1.3785	USDCHF	0.81075